Question 1

vWF activity may become normal in patients with vWD:

Accepted Answer

A)  During inflammation 
B)  During pregnancy 
C)  After transfusions with factor VIII 
D)  All of the above 
E)  None of the above 
A)  During inflammation 
B)  During pregnancy 
C)  After transfusions with factor VIII 
D)  All of the above 
E)  None of the above

Question 2

In most one-stage quantitative assay method for factors VIII, IX, XI, and XII, a 1:10 dilution is considered __________ percent factor activity.

Accepted Answer

A)  50 
B)  100 
C)  75 
D)  25 
E)  None of the above 
A)  50 
B)  100 
C)  75 
D)  25 
E)  None of the above

Question 3

In platelet aggregation, the addition of an aggregating agent causes the formation of large aggregates of platelets, which corresponds to a(n) __________ in light transmittance when using a platelet aggregometer.

Accepted Answer

A)  Increase 
B)  Decrease 
C)  No effect 
D)  All of the above 
E)  None of the above 
A)  Increase 
B)  Decrease 
C)  No effect 
D)  All of the above 
E)  None of the above

Question 4

In the platelet neutralization procedure for lupus anticoagulants (LAs), after mixing LA plasma with freeze-thawed platelet lysate, the __________ will be shortened.

Accepted Answer

A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above 
A)  PT 
B)  APTT 
C)  TT 
D)  Reptilase time 
E)  None of the above

Question 5

The __________ is a measure of the extrinsic and common pathways of coagulation involving factors II, V, VII, and X (as well as fibrinogen).

Accepted Answer

A)  APTT 
B)  Prothrombin time (PT) 
C)  Thrombin time (TT) 
D)  Reptilase time 
E)  None of the above 
A)  APTT 
B)  Prothrombin time (PT) 
C)  Thrombin time (TT) 
D)  Reptilase time 
E)  None of the above

Question 6

If a patient's APTT is normal, but their PT is prolonged, this could be due to:

Accepted Answer

A)  Liver disease 
B)  Factor VII deficiency 
C)  Vitamin K deficiency 
D)  Anti-vitamin K therapy 
E)  All of the above 
A)  Liver disease 
B)  Factor VII deficiency 
C)  Vitamin K deficiency 
D)  Anti-vitamin K therapy 
E)  All of the above

Question 7

Aspirin-containing compounds inhibit the __________ wave of aggregation by inhibiting the release reaction of the platelets.

Accepted Answer

A)  Primary 
B)  Secondary 
C)  Tertiary 
D)  All of the above 
E)  None of the above 
A)  Primary 
B)  Secondary 
C)  Tertiary 
D)  All of the above 
E)  None of the above

Question 8

In patients with __________, the PT is prolonged as a result of a change in the ratio of anticoagulant to plasma.

Accepted Answer

A)  Iron-deficiency anemia 
B)  Thalassemia 
C)  Polycythemia 
D)  Liver disease 
E)  None of the above 
A)  Iron-deficiency anemia 
B)  Thalassemia 
C)  Polycythemia 
D)  Liver disease 
E)  None of the above

Question 9

Abnormal ristocetin-induced platelet aggregation may occur in patients with:

Accepted Answer

A)  Bernard-Soulier syndrome 
B)  Platelet storage pool defects 
C)  Idiopathic thrombocytopenic purpura (ITP) 
D)  All of the above 
E)  None of the above 
A)  Bernard-Soulier syndrome 
B)  Platelet storage pool defects 
C)  Idiopathic thrombocytopenic purpura (ITP) 
D)  All of the above 
E)  None of the above

Question 10

All of the following interfere with the functional protein S assay performed with mechanical clot detection except:

Accepted Answer

A)  2 IU/mL unfractionated heparin 
B)  Activated protein C resistance 
C)  Lipemia 
D)  Oral anticoagulants 
E)  None of the above 
A)  2 IU/mL unfractionated heparin 
B)  Activated protein C resistance 
C)  Lipemia 
D)  Oral anticoagulants 
E)  None of the above

Question 11

In performing platelet aggregation studies, hemolyzed specimens cannot be used because red blood cells (RBCs) contain __________.

Accepted Answer

A)  Spectrin 
B)  Iron 
C)  ADP 
D)  Glycoprotein 
E)  None of the above 
A)  Spectrin 
B)  Iron 
C)  ADP 
D)  Glycoprotein 
E)  None of the above

Question 12

Patients with __________ show a decrease in factor VIII antigen.

Accepted Answer

A)  Hemophilia A 
B)  vWD 
C)  Female carriers of hemophilia A 
D)  All of the above 
E)  None of the above 
A)  Hemophilia A 
B)  vWD 
C)  Female carriers of hemophilia A 
D)  All of the above 
E)  None of the above

Question 13

Clot-based procedures in coagulation are mostly performed at what temperature?

Accepted Answer

A)  22°C ± 5° 
B)  4°C ± 1° 
C)  37°C ± 1° 
D)  56°C ± 1° 
E)  None of the above 
A)  22°C ± 5° 
B)  4°C ± 1° 
C)  37°C ± 1° 
D)  56°C ± 1° 
E)  None of the above

Question 14

The ability of platelets to adhere to one another is a process known as __________.

Accepted Answer

A)  Adhesion 
B)  Aggregation 
C)  Retraction 
D)  All of the above 
E)  None of the above 
A)  Adhesion 
B)  Aggregation 
C)  Retraction 
D)  All of the above 
E)  None of the above

Question 15

The activated partial thromboplastin time (APTT) is a screening test to measure the __________ pathway of coagulation.

Accepted Answer

A)  Intrinsic 
B)  Extrinsic 
C)  Common 
D)  A and C 
E)  All of the above 
A)  Intrinsic 
B)  Extrinsic 
C)  Common 
D)  A and C 
E)  All of the above

Question 16

What is the dilution buffer used in the determination of fibrinogen activity?

Accepted Answer

A)  Electrolyte buffer 
B)  Tris buffer 
C)  Owren's Veronal buffer 
D)  All of the above 
E)  None of the above 
A)  Electrolyte buffer 
B)  Tris buffer 
C)  Owren's Veronal buffer 
D)  All of the above 
E)  None of the above

Question 17

Which anticoagulant is used for samples to be tested in the reptilase test?

Accepted Answer

A)  EDTA 
B)  Sodium citrate, 3.2% 
C)  Sodium oxalate 
D)  Sodium heparin 
E)  None of the above 
A)  EDTA 
B)  Sodium citrate, 3.2% 
C)  Sodium oxalate 
D)  Sodium heparin 
E)  None of the above

Question 18

In patients with severe von Willebrand's disease (vWD), aggregation to __________ is characteristically severely reduced or absent.

Accepted Answer

A)  Serotonin 
B)  Epinephrine 
C)  Ristocetin 
D)  Thrombin 
E)  None of the above 
A)  Serotonin 
B)  Epinephrine 
C)  Ristocetin 
D)  Thrombin 
E)  None of the above

Question 19

When performing an APTT, the addition of normal plasma __________ the clotting time in the presence of a lupus anticoagulant.

Accepted Answer

A)  Will correct. 
B)  Will not correct. 
C)  Will not change. 
D)  All of the above 
E)  None of the above 
A)  Will correct. 
B)  Will not correct. 
C)  Will not change. 
D)  All of the above 
E)  None of the above

Question 20

The patient should be instructed not to take any aspirin-containing drugs__________ before the bleeding time test.

Accepted Answer

A)  48 hours 
B)  24 hours 
C)  1 week 
D)  12 hours 
E)  None of the above 
A)  48 hours 
B)  24 hours 
C)  1 week 
D)  12 hours 
E)  None of the above

Exam 33: Coagulation Procedures

vWF activity may become normal in patients with vWD:

In most one-stage quantitative assay method for factors VIII, IX, XI, and XII, a 1:10 dilution is considered __________ percent factor activity.

In platelet aggregation, the addition of an aggregating agent causes the formation of large aggregates of platelets, which corresponds to a(n) __________ in light transmittance when using a platelet aggregometer.

In the platelet neutralization procedure for lupus anticoagulants (LAs), after mixing LA plasma with freeze-thawed platelet lysate, the __________ will be shortened.

The __________ is a measure of the extrinsic and common pathways of coagulation involving factors II, V, VII, and X (as well as fibrinogen).

If a patient's APTT is normal, but their PT is prolonged, this could be due to:

Aspirin-containing compounds inhibit the __________ wave of aggregation by inhibiting the release reaction of the platelets.

In patients with __________, the PT is prolonged as a result of a change in the ratio of anticoagulant to plasma.

Abnormal ristocetin-induced platelet aggregation may occur in patients with:

All of the following interfere with the functional protein S assay performed with mechanical clot detection except:

In performing platelet aggregation studies, hemolyzed specimens cannot be used because red blood cells (RBCs) contain __________.

Patients with __________ show a decrease in factor VIII antigen.

Clot-based procedures in coagulation are mostly performed at what temperature?

The ability of platelets to adhere to one another is a process known as __________.

The activated partial thromboplastin time (APTT) is a screening test to measure the __________ pathway of coagulation.

What is the dilution buffer used in the determination of fibrinogen activity?

Which anticoagulant is used for samples to be tested in the reptilase test?

In patients with severe von Willebrand's disease (vWD), aggregation to __________ is characteristically severely reduced or absent.

When performing an APTT, the addition of normal plasma __________ the clotting time in the presence of a lupus anticoagulant.

The patient should be instructed not to take any aspirin-containing drugs__________ before the bleeding time test.

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Disorders of Plasma Clotting Factors

Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters